Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Equity Income (2020 - 2025)

Historic Equity Income for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $4.9 million.

  • Beam Therapeutics' Equity Income rose 33919.57% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 14503.46%. This contributed to the annual value of -$14.1 million for FY2024, which is 2419.86% up from last year.
  • As of Q3 2025, Beam Therapeutics' Equity Income stood at $4.9 million, which was up 33919.57% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Equity Income ranged from a high of $25.8 million in Q2 2021 and a low of -$25.5 million during Q3 2022
  • Moreover, its 5-year median value for Equity Income was -$2.7 million (2024), whereas its average is -$2.5 million.
  • As far as peak fluctuations go, Beam Therapeutics' Equity Income skyrocketed by 489303.68% in 2021, and later crashed by 83965.35% in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' Equity Income stood at -$4.3 million in 2021, then tumbled by 497.19% to -$25.5 million in 2022, then soared by 97.17% to -$722000.0 in 2023, then plummeted by 50.97% to -$1.1 million in 2024, then surged by 552.94% to $4.9 million in 2025.
  • Its last three reported values are $4.9 million in Q3 2025, $4.4 million for Q2 2025, and -$2.1 million during Q1 2025.